Using AI on CT and MRI scans to predict immunotherapy response and survival for liver cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Researchers will collect pre-treatment (and possibly post-treatment) CT and MR images from hepatocellular carcinoma patients treated at Union Hospital between July 2025 and July 2026 and link them with clinical outcomes. An automated pipeline will segment tumors, extract radiomics features, select the most informative features, and train machine-learning classification models to predict immunotherapy response and survival. Patients with poor image quality, incomplete data, another primary cancer, or unclear pathology will be excluded to preserve model reliability. The work is observational and based on retrospective clinical imaging and pathology data from a single center in Wuhan.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients were treated for hepatocellular carcinoma in Wuhan Union Hospital from July 2025 to July 2026;
2. Aged \> 18 years old;
3. At least one CT scan or MR scan before treatment;
4. Tissue biopsy pathological examination confirmed the diagnosis of the above tumors.

Exclusion criteria:

1. Poor image quality;
2. Incomplete clinical data or loss of follow-up;
3. Presence of another primary malignancy other than liver cancer;
4. Unclear pathological diagnosis.

Where it's running

• Union Hospital，Tongji Medical College，Huazhong University of Science and Technology
  Wuhan, Hubei, China Recruiting

Study contacts

• Study coordinator: Lian Yang
• Email: yanglian@hust.edu.cn
• Phone: 18986273791

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PULSAR radiotherapy plus immunotherapy for high-risk advanced liver cancer

  This study tests whether adding PULSAR radiotherapy to standard immunotherapy helps adults with high‑risk advanced liver cancer live longer without their cancer progressing.

  Recruiting Phase 2 Samsung Medical Center · Seoul · NCT07884877

• AI-guided treatment choices for advanced liver cancer

  Researchers are testing an AI tool to help predict which patients with advanced hepatocellular carcinoma will respond to modern systemic therapies.

  Recruiting at 5 sites Universitaire Ziekenhuizen KU Leuven · Anderlecht and 4 other locations · NCT07863258

• Intratumoral oncolytic virus plus immune checkpoint inhibitors in metastatic colorectal, gastric, or liver cancer

  Doctors are testing whether injecting an oncolytic virus directly into tumors along with immune checkpoint drugs is safe and may help people with advanced colorectal, gastric, or liver cancer who have tried many treatments.

  Recruiting Foshan Fosun Chancheng Hospital · Guangdong, Foshan · NCT07850882

• Biomarker testing to predict treatment response and recurrence in liver cancer

  This study tests biomarkers in adults with hepatocellular carcinoma to see if they can predict how well treatments work and the chance of the cancer coming back.

  Recruiting Tianjin Medical University Cancer Institute and Hospital · Tianjin · NCT07840092

• MRI plus diffusion and CEST imaging to map liver cancer and its immune environment

  This study tests whether adding an extra MRI sequence can help see how the liver cancer microenvironment changes and relate those changes to immune activity in patients with hepatocellular carcinoma.

  Recruiting Tongji Hospital · Wuhan, Hubei · NCT07838415

• Irreversible Electroporation Added to Targeted Therapy and Immunotherapy for Advanced HCC

  This study tests whether adding irreversible electroporation to lenvatinib and sintilimab can help patients with unresectable advanced hepatocellular carcinoma see bigger tumor shrinkage and become eligible for surgery.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, No. 1 Shuaifuyuan, Dongcheng District, Beijing, China · NCT07832006

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.